Regen BioPharmaRGBP +100.00% 3-Year ROIIC % is -0.05 as of Sep. 2025. The stock has 7 warning signs investors should review. Among 1,323 Biotechnology companies, Regen BioPharma ranks better than 52.53% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Regen BioPharma's 3-Year ROIIC % for the quarter that ended in Sep. 2025 was -0.05%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Regen BioPharma's 3-Year ROIIC % or its related term are showing as below:
RGBP's 3-Year ROIIC % is ranked better than 52.53% of 1323
companies
in the Biotechnology industry
Industry Median: -4.82
vs RGBP: -0.05
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Regen BioPharma 3-Year ROIIC % Related Terms
Regen BioPharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs SIGY, ENDV, CNBX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Regen BioPharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's 3-Year ROIIC % falls into.
Regen BioPharma's 3-Year ROIIC % for the quarter that ended in Sep. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.339 (Sep. 2025) - -0.34 (Sep. 2022) )
/
( 4.716 (Sep. 2025) - 6.767 (Sep. 2022) )
=
0.001
/
-2.051
=
-0.05%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Regen BioPharma (RGBP) has a 3-Year ROIIC % of -0.05 as of Sep. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #628 out of 1323 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Regen BioPharma's 3-Year ROIIC % too high?
Regen BioPharma's current 3-Year ROIIC % is -0.05. Based on the distribution chart, Regen BioPharma ranks #628 out of 1323 companies in the Biotechnology industry, which is above the industry midpoint.
How does Regen BioPharma's 3-Year ROIIC % compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #628 out of 1323 companies for 3-Year ROIIC %. This puts Regen BioPharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current 3-Year ROIIC % is -0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current 3-Year ROIIC % is -0.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current 3-Year ROIIC % is -0.05 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 